Pharmacopoeia Commission: More than 300 varieties [identification] items involve deletion!

Source: Pharmacopoeia Commission: wangxinglai2004

On October 27, 2022, the State Pharmacopoeia Commission issued the Notice on the Announcement of the Draft Revision of the National Standard for the 2020 Second Part of the Chinese Pharmacopoeia of 319 Chinese Pharmacopoeia including Dihydroxyprophylline, of which more than 300 varieties deleted individual identification items, and the publicity period was one month
from the date of publication.

Our committee intends to revise 319 national standards for the 2020 edition of the second part of the Chinese Pharmacopoeia, including dihydroxyprophylline, and the standard number: the second part of the 2020 edition of the Chinese Pharmacopoeia
.

In order to ensure the scientificity, rationality and applicability of the standard, the national standards for 319 varieties of the 2020 edition of the Chinese Pharmacopoeia, including dihydroxyprophylline, are hereby announced for comments from all walks of life (see the annex for details).

The publicity period is one month
from the date of publication.

Please study carefully, if there is any objection, please write to submit feedback in time, with relevant instructions, experimental data and contact information
.
The relevant letter must be stamped with an official seal, the personal letter must be signed by the person, and the electronic version should be sent to the designated email address
.

Contact: Wang Zhijun; GUO Wei

Tel:010-67079559; 010-67079558

Email: wangzhijun@chp.
org.
cn

Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahuananli, Dongcheng District, Beijing

Zip code: 100061

Scan the QR code to view the original article